214 related articles for article (PubMed ID: 28776551)
1. Advances in Pathobiology of Primary Central Nervous System Lymphoma.
Yang XL; Liu YB
Chin Med J (Engl); 2017 Aug; 130(16):1973-1979. PubMed ID: 28776551
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
Kreher S; Jöhrens K; Strehlow F; Martus P; Borowiec K; Radke J; Heppner F; Roth P; Thiel E; Pietsch T; Weller M; Korfel A
Neuro Oncol; 2015 Jul; 17(7):1016-21. PubMed ID: 25817328
[TBL] [Abstract][Full Text] [Related]
3. Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma.
Coupland SE; Loddenkemper C; Smith JR; Braziel RM; Charlotte F; Anagnostopoulos I; Stein H
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):3957-64. PubMed ID: 16249468
[TBL] [Abstract][Full Text] [Related]
4. Insights into the biology of primary central nervous system lymphoma.
Mrugala MM; Rubenstein JL; Ponzoni M; Batchelor TT
Curr Oncol Rep; 2009 Jan; 11(1):73-80. PubMed ID: 19080745
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation attenuates SHP1 expression and function in patients with primary central nervous system lymphoma.
Liu J; Wang Y; Sun X; Ji N; Sun S; Wang Y; Liu F; Cui Q; Wang C; Liu Y
Oncol Rep; 2017 Feb; 37(2):887-894. PubMed ID: 27959415
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.
Kim HO; Kim JS; Kim SO; Chae SY; Oh SJ; Seo M; Lee SH; Oh JS; Ryu JS; Huh JR; Kim JH
Medicine (Baltimore); 2020 May; 99(20):e20140. PubMed ID: 32443328
[TBL] [Abstract][Full Text] [Related]
7. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma.
Braaten KM; Betensky RA; de Leval L; Okada Y; Hochberg FH; Louis DN; Harris NL; Batchelor TT
Clin Cancer Res; 2003 Mar; 9(3):1063-9. PubMed ID: 12631608
[TBL] [Abstract][Full Text] [Related]
8. [Effect of B Cell Differentiation Markers on the Prognosis of Primary Central Nervous System Lymphoma].
Chen XL; Li XY; Wang W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1410-1414. PubMed ID: 29070116
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical Expression of CD10, BCL6 and MUM1 in Differentiating Diffuse Large B Cell Lymphoma Subtypes.
Bajwa AA; Khadim MT; Din HU; Ali SS; Jamil U; Khan UAS
J Coll Physicians Surg Pak; 2017 Oct; 27(10):621-624. PubMed ID: 29056123
[TBL] [Abstract][Full Text] [Related]
10. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
[TBL] [Abstract][Full Text] [Related]
11. Immunohistological profiling by B-cell differentiation status of primary central nervous system lymphoma treated by high-dose methotrexate chemotherapy.
Kinoshita M; Hashimoto N; Izumoto S; Okita Y; Kagawa N; Maruno M; Ohnishi T; Arita N; Yoshimine T
J Neurooncol; 2010 Aug; 99(1):95-101. PubMed ID: 20069343
[TBL] [Abstract][Full Text] [Related]
12. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice.
Deckert M; Montesinos-Rongen M; Brunn A; Siebert R
Acta Neuropathol; 2014 Feb; 127(2):175-88. PubMed ID: 24240734
[TBL] [Abstract][Full Text] [Related]
13. LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.
Lossos C; Bayraktar S; Weinzierl E; Younes SF; Hosein PJ; Tibshirani RJ; Sutton Posthumus J; DeAngelis LM; Raizer J; Schiff D; Abrey L; Natkunam Y; Lossos IS
Br J Haematol; 2014 Jun; 165(5):640-8. PubMed ID: 24571259
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.
Lin CH; Kuo KT; Chuang SS; Kuo SH; Chang JH; Chang KC; Hsu HC; Tien HF; Cheng AL
Clin Cancer Res; 2006 Feb; 12(4):1152-6. PubMed ID: 16489068
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of the immunohistochemical subtypes and prognosis of primary diffuse large B cell lymphoma of the central nervous system].
Min M; Lin L; Bi CF; Wang XQ; Luo TY; Zhao S; Zhang WY; Liu WP
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):110-6. PubMed ID: 22780928
[TBL] [Abstract][Full Text] [Related]
16. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.
D'Haene N; Catteau X; Maris C; Martin B; Salmon I; Decaestecker C
Br J Haematol; 2008 Feb; 140(4):402-10. PubMed ID: 18081894
[TBL] [Abstract][Full Text] [Related]
17. Primary central nervous system lymphoma: a clinicopathological study of 75 cases.
Preusser M; Woehrer A; Koperek O; Rottenfusser A; Dieckmann K; Gatterbauer B; Roessler K; Slavc I; Jaeger U; Streubel B; Hainfellner JA; Chott A
Pathology; 2010; 42(6):547-52. PubMed ID: 20854073
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis in primary central nervous system lymphoma (PCNSL).
Takeuchi H; Matsuda K; Kitai R; Sato K; Kubota T
J Neurooncol; 2007 Sep; 84(2):141-5. PubMed ID: 17406788
[TBL] [Abstract][Full Text] [Related]
19. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.
Braggio E; Van Wier S; Ojha J; McPhail E; Asmann YW; Egan J; da Silva JA; Schiff D; Lopes MB; Decker PA; Valdez R; Tibes R; Eckloff B; Witzig TE; Stewart AK; Fonseca R; O'Neill BP
Clin Cancer Res; 2015 Sep; 21(17):3986-94. PubMed ID: 25991819
[TBL] [Abstract][Full Text] [Related]
20. Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis.
Shi H; Sun X; Wu Y; Cui Q; Sun S; Ji N; Liu Y
J Clin Neurosci; 2024 Jun; 124():36-46. PubMed ID: 38642434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
